🏛️ Verified NIH Record • Updated 2026-06-05
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis (NCT06106672)
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: COUR Pharmaceutical Development Company, Inc.
🩺 Plain-English Summary (8th-Grade Level)
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Who can join: Review the eligibility criteria below.
Location: Barrow Neurological Institute — Phoenix, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Barrow Neurological Institute — Phoenix, Arizona
- Infusion for Health — Brea, California
- University of California, Irvine — Orange, California
- University of California, Davis — Sacramento, California
- Yale University — New Haven, Connecticut
- Atlantis Research — Miami, Florida
- Quantix Research, LLC — Miami, Florida
- University of South Florida — Tampa, Florida
- Insight Hospital and Medical Center — Chicago, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- Insight Research Institute, Dearborn — Dearborn, Michigan
- University of Missouri, NextGen Precision Health — Columbia, Missouri
- Ohio State University Wexner Medical Center — Colombus, Ohio
- Medical University of South Carolina — Charleston, South Carolina
- Nerve and Muscle Center of Texas — Houston, Texas
- Prolato Clinical Research Center — Houston, Texas
- Virginia Commonwealth University — Richmond, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myasthenia Gravis
- Myasthenia Gravis Inebilizumab Trial — Orange, California
- Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis — Boston, Massachusetts
- Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis — Saint Paul, Minnesota
- A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis — Phoenix, Arizona
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) — Colorado Springs, Colorado
Explore by condition: All Myasthenia Gravis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.